Related references
Note: Only part of the references are listed.Increased mortality and aggravation of heart failure in liver X receptor-α knockout mice after myocardial infarction
Xiaoqiang Liu et al.
HEART AND VESSELS (2016)
Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis
Atsushi Miyamoto et al.
INTERNAL MEDICINE (2016)
The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice
Xingxu Wang et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2016)
Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts
Kiyoshi Yamagami et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2015)
Cardiac LXR protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization
Megan V. Cannon et al.
EMBO MOLECULAR MEDICINE (2015)
The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects
Megan V. Cannon et al.
EUROPEAN JOURNAL OF HEART FAILURE (2015)
Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP
Nan Li et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2015)
Renal Denervation Findings on Cardiac and Renal Fibrosis in Rats with Isoproterenol Induced Cardiomyopathy
Qian Liu et al.
SCIENTIFIC REPORTS (2015)
Efficient long-term survival of cell grafts after myocardial infarction with thick viable cardiac tissue entirely from pluripotent stem cells
Takehiko Matsuo et al.
SCIENTIFIC REPORTS (2015)
Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages
Christian Beyer et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Improving vagal activity ameliorates cardiac fibrosis induced by angiotensin II: in vivo and in vitro
Jin-Jun Liu et al.
SCIENTIFIC REPORTS (2015)
Activation of Liver X Receptor Improves Viability of Adipose-Derived Mesenchymal Stem Cells to Attenuate Myocardial Ischemia Injury Through TLR4/NF-κB and Keap-1/Nrf-2 Signaling Pathways
Yabin Wang et al.
ANTIOXIDANTS & REDOX SIGNALING (2014)
Functional and structural impact of pirfenidone on the alterations of cardiac disease and diabetes mellitus
Guillermo Avila et al.
CELL CALCIUM (2014)
Expression of Liver X Receptor Correlates with Intrahepatic Inflammation and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
Sang Bong Ahn et al.
DIGESTIVE DISEASES AND SCIENCES (2014)
Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts
Enrico Conte et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Angiotensin II regulates ACE and ACE2 in neurons through p38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2 signaling
Liang Xiao et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2013)
Angiotensin-(1-7): beyond the cardio-renal actions
Danielle G. Passos-Silva et al.
CLINICAL SCIENCE (2013)
Loss of Angiotensin-Converting Enzyme-2 Exacerbates Diabetic Cardiovascular Complications and Leads to Systolic and Vascular Dysfunction A Critical Role of the Angiotensin II/AT1 Receptor Axis
Vaibhav B. Patel et al.
CIRCULATION RESEARCH (2012)
Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases
Bhoomika M. Patel et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
Long-term oral Asperosaponin VI attenuates cardiac dysfunction, myocardial fibrosis in a rat model of chronic myocardial infarction
Chunmei Li et al.
FOOD AND CHEMICAL TOXICOLOGY (2012)
Renoprotective properties of pirfenidone in subtotally nephrectomized rats
Koji Takakuta et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Effects and mechanism of irbesartan on tubulointerstitial fibrosis in 5/6 nephrectomized rats
Gang Zhao et al.
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES (2010)
Activation of liver X receptor-α reduces activation of the renal and cardiac renin-angiotensin-aldosterone system
Irma Kuipers et al.
LABORATORY INVESTIGATION (2010)
Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction
Justin F. X. Ainscough et al.
CARDIOVASCULAR RESEARCH (2009)
Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway
Vijay Koka et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology
Shant Der Sarkissian et al.
HYPERTENSION (2008)
GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats
C. E. Leik et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches
Junya Takagawa et al.
JOURNAL OF APPLIED PHYSIOLOGY (2007)
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2
CM Ferrario et al.
CIRCULATION (2005)
Share Paper
